{"title":"糜烂性脓疱性皮肤病与阿米万他单抗治疗肺癌1例报告。","authors":"Yseult Senterre, Amandine Bouillenne, Murielle Sabatiello, Anne-Sophie Demoulin, Arjen F Nikkels","doi":"10.1159/000546616","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Amivantamab is a monoclonal antibody against EGFR and MET receptors, indications for certain types of non-small cell lung cancer. Due to its mechanisms, cutaneous adverse effects are frequent and numerous.</p><p><strong>Case presentation: </strong>A 67-year-old woman with metastatic adenosquamous carcinoma, stage T3N2M1c, was treated with amivantamab after the first-line chemotherapy failed. Despite prophylactic oral tetracyclines, she developed severe erosive pustular dermatosis (EPD) affecting more than 50% of her scalp, forcing to cut short her hair to provide adequate local care.</p><p><strong>Conclusion: </strong>EPD is an exceptional and severe adverse event of amivantamab, requiring oral steroids, tetracyclines and appropriate local care with antibiotic creams. Clinicians should be aware of this complication as early therapeutic intervention is mandatory to avoid deleterious consequences and spontaneous recurrences.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"17 1","pages":"263-267"},"PeriodicalIF":0.9000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240574/pdf/","citationCount":"0","resultStr":"{\"title\":\"Erosive Pustular Dermatosis and Amivantamab for Lung Cancer: A Case Report.\",\"authors\":\"Yseult Senterre, Amandine Bouillenne, Murielle Sabatiello, Anne-Sophie Demoulin, Arjen F Nikkels\",\"doi\":\"10.1159/000546616\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Amivantamab is a monoclonal antibody against EGFR and MET receptors, indications for certain types of non-small cell lung cancer. Due to its mechanisms, cutaneous adverse effects are frequent and numerous.</p><p><strong>Case presentation: </strong>A 67-year-old woman with metastatic adenosquamous carcinoma, stage T3N2M1c, was treated with amivantamab after the first-line chemotherapy failed. Despite prophylactic oral tetracyclines, she developed severe erosive pustular dermatosis (EPD) affecting more than 50% of her scalp, forcing to cut short her hair to provide adequate local care.</p><p><strong>Conclusion: </strong>EPD is an exceptional and severe adverse event of amivantamab, requiring oral steroids, tetracyclines and appropriate local care with antibiotic creams. Clinicians should be aware of this complication as early therapeutic intervention is mandatory to avoid deleterious consequences and spontaneous recurrences.</p>\",\"PeriodicalId\":9619,\"journal\":{\"name\":\"Case Reports in Dermatology\",\"volume\":\"17 1\",\"pages\":\"263-267\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240574/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Dermatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000546616\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000546616","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Erosive Pustular Dermatosis and Amivantamab for Lung Cancer: A Case Report.
Introduction: Amivantamab is a monoclonal antibody against EGFR and MET receptors, indications for certain types of non-small cell lung cancer. Due to its mechanisms, cutaneous adverse effects are frequent and numerous.
Case presentation: A 67-year-old woman with metastatic adenosquamous carcinoma, stage T3N2M1c, was treated with amivantamab after the first-line chemotherapy failed. Despite prophylactic oral tetracyclines, she developed severe erosive pustular dermatosis (EPD) affecting more than 50% of her scalp, forcing to cut short her hair to provide adequate local care.
Conclusion: EPD is an exceptional and severe adverse event of amivantamab, requiring oral steroids, tetracyclines and appropriate local care with antibiotic creams. Clinicians should be aware of this complication as early therapeutic intervention is mandatory to avoid deleterious consequences and spontaneous recurrences.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
